These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

895 related articles for article (PubMed ID: 18397336)

  • 21. Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes.
    Baudoux P; Lemaire S; Denis O; Tulkens PM; Van Bambeke F; Glupczynski Y
    J Antimicrob Chemother; 2010 Jun; 65(6):1228-36. PubMed ID: 20378672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activities of tigecycline, daptomycin, linezolid and quinupristin/dalfopristin against glycopeptide-resistant Enterococcus faecium.
    Abb J
    Int J Antimicrob Agents; 2007 Mar; 29(3):358-60. PubMed ID: 17229553
    [No Abstract]   [Full Text] [Related]  

  • 23. Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan.
    Luh KT; Hsueh PR; Teng LJ; Pan HJ; Chen YC; Lu JJ; Wu JJ; Ho SW
    Antimicrob Agents Chemother; 2000 Dec; 44(12):3374-80. PubMed ID: 11083643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the MicroScan system and the agar dilution assay for Quinupristin/Dalfopristin susceptibility of Enterococcus faecium.
    Kim YR; Kim SI; Hur JA; Kim YJ; Wie SH; Park YJ; Kang MW
    Ann Clin Lab Sci; 2007; 37(3):260-2. PubMed ID: 17709691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit.
    Johnson AP; Tysall L; Stockdale MV; Woodford N; Kaufmann ME; Warner M; Livermore DM; Asboth F; Allerberger FJ
    Eur J Clin Microbiol Infect Dis; 2002 Oct; 21(10):751-4. PubMed ID: 12415476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report.
    Swoboda S; Fritz S; Martignoni ME; Feldhues RA; Hoppe-Tichy T; Buchler MW; Geiss HK
    J Antimicrob Chemother; 2005 Oct; 56(4):787-9. PubMed ID: 16143710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activities of quinupristin/dalfopristin and eight other antimicrobial agents against 360 clinical isolates from Korea.
    Hwang SH; Kim MN; Pai CH; Huh DH; Shin WS
    Yonsei Med J; 2000 Oct; 41(5):563-9. PubMed ID: 11079615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections.
    Raad I; Hachem R; Hanna H; Afif C; Escalante C; Kantarjian H; Rolston K
    J Antimicrob Chemother; 2004 Apr; 53(4):646-9. PubMed ID: 14998986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quinupristin-dalfopristin and linezolid: evidence and opinion.
    Eliopoulos GM
    Clin Infect Dis; 2003 Feb; 36(4):473-81. PubMed ID: 12567306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vancomycin-resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin.
    Rathe M; Kristensen L; Ellermann-Eriksen S; Thomsen MK; Schumacher H
    APMIS; 2010 Jan; 118(1):66-73. PubMed ID: 20041873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.
    Kuti JL; Kiffer CR; Mendes CM; Nicolau DP
    Clin Microbiol Infect; 2008 Feb; 14(2):116-23. PubMed ID: 18076672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm.
    Weigel LM; Donlan RM; Shin DH; Jensen B; Clark NC; McDougal LK; Zhu W; Musser KA; Thompson J; Kohlerschmidt D; Dumas N; Limberger RJ; Patel JB
    Antimicrob Agents Chemother; 2007 Jan; 51(1):231-8. PubMed ID: 17074796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Linezolid-resistant Enterococcus faecium and Enterococcus faecalis isolated from a septic patient: report of first isolates in Germany.
    Halle E; Padberg J; Rosseau S; Klare I; Werner G; Witte W
    Infection; 2004 Jun; 32(3):182-3. PubMed ID: 15188081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance.
    Chong YP; Lee SO; Song EH; Lee EJ; Jang EY; Kim SH; Choi SH; Kim MN; Jeong JY; Woo JH; Kim YS
    Scand J Infect Dis; 2010 Jul; 42(6-7):491-9. PubMed ID: 20524781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Activity of vancomycin and teicoplanin against clinical isolates of Staphylococcus aureus in the period 1994-1999].
    Nashev D; Toshkova K; Gavrilova V
    Vutr Boles; 2000; 32(2):35-40. PubMed ID: 11227664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Linezolid resistance in Enterococcus faecium isolated in Ontario, Canada.
    Patel SN; Memari N; Shahinas D; Toye B; Jamieson FB; Farrell DJ
    Diagn Microbiol Infect Dis; 2013 Dec; 77(4):350-3. PubMed ID: 24095643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype.
    Pillai SK; Sakoulas G; Wennersten C; Eliopoulos GM; Moellering RC; Ferraro MJ; Gold HS
    J Infect Dis; 2002 Dec; 186(11):1603-7. PubMed ID: 12447736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.
    Rybak MJ; Hershberger E; Moldovan T; Grucz RG
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1062-6. PubMed ID: 10722513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The post-antibiotic effects of linezolid against Gram-positive pathogens.
    Hosgor-Limoncu M; Ermertcan S; Tasli H; Aydemir S
    Saudi Med J; 2007 Apr; 28(4):551-4. PubMed ID: 17457476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.